Details

Autor(en) / Beteiligte

• Akhvlediani, Tamar
• Bernard‐Valnet, Raphael
• Dias, Sara P.
• Eikeland, Randi
• Pfausler, Bettina
• Sellner, Johann

Titel

Neurological side effects and drug interactions of antiviral compounds against SARS‐CoV‐2

Ist Teil von

• European journal of neurology, 2023-12, Vol.30 (12), p.3904-3912

Ort / Verlag

England: John Wiley & Sons, Inc

Erscheinungsjahr

2023

Quelle

Wiley Online Library Journals

Beschreibungen/Notizen

• Background and purpose The COVID‐19 pandemic, caused by severe acute respiratory syndrome coronavirus type 2 (SARS‐CoV‐2), rapidly spread across the globe. Tremendous efforts have been mobilized to create effective antiviral treatment options to reduce the burden of the disease. This article summarizes the available knowledge about the antiviral drugs against SARS‐CoV‐2 from a neurologist's perspective. Methods We summarize neurological aspects of antiviral compounds against SARS‐CoV‐2 with full, conditional, or previous marketing authorization by the European Medicines Agency (EMA). Results Nirmatrelvir/ritonavir targets the SARS‐CoV‐2 3c‐like protease using combinatorial chemistry. Nirmatrelvir/ritonavir levels are affected by medications metabolized by or inducing CYP3A4, including those used in neurological diseases. Dysgeusia with a bitter or metallic taste is a common side effect of nirmatrelvir/ritonavir. Molnupiravir is a nucleotide analog developed to inhibit the replication of viruses. No clinically significant interactions with other drugs have been identified, and no specific considerations for people with neurological comorbidity are required. In the meantime, inconsistent results from clinical trials regarding efficacy have led to the withdrawal of marketing authorization by the EMA. Remdesivir is a viral RNA polymerase inhibitor and interferes with the production of viral RNA. The most common side effect in patients with COVID‐19 is nausea. Remdesivir is a substrate for CYP3A4. Conclusions Neurological side effects and drug interactions must be considered for antiviral compounds against SARS‐CoV‐2. Further studies are required to better evaluate their efficacy and adverse events in patients with concomitant neurological diseases. Moreover, evidence from real‐world studies will complement the current knowledge.